RT Journal Article
SR Electronic
T1 Antibody neutralization to SARS-CoV-2 and variants after one year in Wuhan
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.16.21258673
DO 10.1101/2021.06.16.21258673
A1 Liu, Qianyun
A1 Xiong, Qing
A1 Mei, Fanghua
A1 Ma, Chengbao
A1 Zhang, Zhen
A1 Hu, Bing
A1 Xu, Junqiang
A1 Jiang, Yongzhong
A1 Zhan, Faxian
A1 Chen, Xianying
A1 Guo, Ming
A1 Wang, Xin
A1 Fang, Yaohui
A1 Shen, Shu
A1 Liu, Yingle
A1 Liu, Fang
A1 Zhou, Li
A1 Xu, Ke
A1 Ke, Changwen
A1 Deng, Fei
A1 Cai, Kun
A1 Yan, Huan
A1 Chen, Yu
A1 Lan, Ke
YR 2021
UL http://medrxiv.org/content/early/2021/06/21/2021.06.16.21258673.abstract
AB Most COVID-19 patients can build effective humoral immunity against SARS-CoV-2 after recovery(1, 2). However, it remains unknown how long the protection can maintain and how efficiently it can protect people from the reinfection of the emerging SARS-CoV-2 variants. Here we evaluated the sera from 248 COVID-19 convalescents around one year post-infection in Wuhan, the earliest epicenter of SARS-CoV-2. We demonstrated that the SARS-CoV-2 immunoglobulin G (IgG) maintains at a high level and potently neutralizes the infection of the original strain (WT) and the B.1.1.7 variant in most patients. However, they showed varying degrees of efficacy reduction against the other variants of concern (P.1, B.1.525, and especially B.1.351) in a patient-specific manner. Mutations in RBD including K417N, E484K, and E484Q/L452R (B.1.617) remarkably impair the neutralizing activity of the convalescents’ sera. Encouragingly, we found that a small fraction of patients’ sera showed broad neutralization potency to multiple variants and mutants, suggesting the existence of broadly neutralizing antibodies recognizing the epitopes beyond the mutation sites. Our results suggest that the SARS-CoV-2 vaccination effectiveness relies more on the timely re-administration of the epitope-updated vaccine than the durability of the neutralizing antibodies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by grants from the National Science and Technology Major Project (2018YFA0900801), China NSFC projects (32041007 and 32070160), Fundamental Research Funds for the Central Universities (2042021kf0220 and 2042020kf0024), the Advanced Customer Cultivation Project of Wuhan National Biosafety Laboratory (2021ACCP-MS10) and Special Fund for COVID-19 Research of Wuhan University. We are grateful to Beijing Taikang Yicai Foundation for their great support to this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All blood donors provided written informed consent for participation in the study. These human sera protocols were approved by the Ethics Committee of Hubei Provincial Center for Disease Control and Prevention, Wuhan, China (No. 2021-012-01)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available in the manuscript or extended data.